With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims
This article was originally published in The Tan Sheet
Executive Summary
In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product
You may also be interested in...
US HBW Executive Decisions: FDA's Zeller Retires; CHPA, GOED Additions; ACI VP On ITAC3
Mitch Zeller retires more than 30 year career in tobacco policy; Logan Tucker joins CHPA communications director; GOED hires Ashely Becnel as global business development director; ACI VP Kathleen Stanton appointed to Industry Trade advisory committee.
FDA Floats Broader Pathway For Nicotine Replacement Therapies
FDA’s report to Congress on tobacco abstinence therapy points toward a “comprehensive strategy” for tobacco and nicotine product regulation, incorporating the work of the drug, device and tobacco centers. Some smoking cessation experts say changes are overdue.
In Brief
FDA works on e-cigarette regulations